Eagle Labs Inc. on Wednesday announced the launch of impirica (www.impirica.co), a new cannabidiol (“CBD”) brand intended to eliminate consumer hesitancy and increase confidence of those interested in trying CBD products. According to the update, Eagle Labs has taken numerous steps to differentiate impirica from other CBD products in the exciting and highly competitive market. “The impirica brand is strategically designed and looks different than most CBD brands — the brand name itself connotes testing and trust, and you won’t find a hemp leaf anywhere on the packaging,” Eagle Labs Chief Commercial Officer Michael Law said in the news release. “In addition, truth and transparency are of the utmost importance, which is why every product we sell has a QR code on the label that takes you directly to the product testing results.”
To view the full press release, visit http://cnw.fm/7oiJx
About Eagle Labs Inc.
Eagle Labs manufactures the highest quality and most rigorously tested nutritional supplements and skin care products in the USA. The company provides complete, flexible formulating and manufacturing services for private label lines, specializing in working with businesses who are interested in developing high-quality products in smaller quantities. In addition, Eagle Labs has its own line of cannabidiol (“CBD”) products under its impirica brand, which includes tinctures, capsules, soft gels, topical skin creams, a roll-on, and a transdermal patch all tested by multiple independent labs to ensure consumer safety. For more information, visit the company’s website at www.EagleLabsInc.com.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]
CBDWire is part of the InvestorBrandNetwork.